Annovis Bio, Inc.
ANVS- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001477845
No open-market purchases or sales by Annovis Bio, Inc. insiders were filed in the last 90 days; 61 institutions reported holding it in 13F filings for Q2 2026, worth $20.2M in total; no superinvestor holds it.
13F holders, Q2 2022
Institutional positions in Annovis Bio, Inc. as of Jun 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 26
- +2 vs. Q1 2022
- Shares held
- 770.5K
- −119.1K (−13.4%) vs. Q1 2022
- Total value
- $8.73M
- −$3.14M (−26.4%) vs. Q1 2022
- New holders
- 3
- 5 more added
- Sold out
- 1
- 9 more reduced
Compare with Q1 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ANVS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 61 | $20.2M |
| Q1 2026 | 56 | $10.5M |
| Q4 2025 | 53 | $14.7M |
| Q3 2025 | 42 | $4.19M |
| Q2 2025 | 42 | $3.93M |
| Q1 2025 | 44 | $3.13M |
| Q4 2024 | 40 | $7.93M |
| Q3 2024 | 35 | $9.50M |
| Q2 2024 | 31 | $5.67M |
| Q1 2024 | 31 | $14.3M |
| Q4 2023 | 36 | $22.5M |
| Q3 2023 | 30 | $10.6M |
| Q2 2023 | 28 | $18.3M |
| Q1 2023 | 23 | $11.6M |
| Q4 2022 | 23 | $9.93M |
| Q3 2022 | 25 | $10.0M |
| Q2 2022 | 26 | $8.73M |
| Q1 2022 | 24 | $11.9M |
| Q4 2021 | 32 | $19.6M |
| Q3 2021 | 38 | $36.2M |
| Q2 2021 | 57 | $109.0M |
| Q1 2021 | 31 | $23.1M |
Institutions, Q2 2022
Shares, value and share of portfolio for each institution holding Annovis Bio, Inc.; share changes are against Q1 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Citigroup Inc | 5 | $0 | 0.00% | −70−93.3% | Reduced |
| Financial Connections Group, Inc. | 25 | $0 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 414 | $5.00K | 0.00% | +414 | New |
| IFP Advisors, Inc | 600 | $6.00K | 0.00% | 00.0% | Unchanged |
| Rockefeller Capital Management L.P. | 1,000 | $11.0K | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 2,070 | $25.0K | 0.00% | −800−27.9% | Reduced |
| FNY Investment Advisers, LLC | 3,650 | $41.0K | 0.03% | +3,050+508.3% | Added |
| Wells Fargo & Company | 8,781 | $99.0K | 0.00% | +40.0% | Added |
| Bank of America Corp | 8,662 | $99.0K | 0.00% | +1,494+20.8% | Added |
| Cannell Peter B & Co Inc | 10,000 | $113.0K | 0.00% | 00.0% | Unchanged |
| Koshinski Asset Management, Inc. | 10,000 | $113.0K | 0.01% | +10,000 | New |
| Essex LLC | 10,408 | $118.0K | 0.04% | −1,185−10.2% | Reduced |
| Lynwood Capital Management Inc. | 12,500 | $142.0K | 0.16% | +12,500 | New |
| Knoll Capital Management, LLC | 14,210 | $161.0K | 0.09% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 16,700 | $189.0K | 0.00% | −6,497−28.0% | Reduced |
| State Street Corp | 17,135 | $194.0K | 0.00% | 00.0% | Unchanged |
| Two Sigma Advisers, LP | 18,000 | $204.0K | 0.00% | −28,400−61.2% | Reduced |
| Bridgeway Capital Management, LLC | 23,600 | $268.0K | 0.01% | 00.0% | Unchanged |
| Bank of New York Mellon Corp | 25,492 | $289.0K | 0.00% | −33−0.1% | Reduced |
| Sterling Investment Advisors, Ltd. | 26,974 | $306.0K | 0.11% | +8,000+42.2% | Added |
| Modera Wealth Management, LLC | 30,913 | $351.0K | 0.02% | −400−1.3% | Reduced |
| Wescott Financial Advisory Group, LLC | 41,607 | $472.0K | 0.13% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 42,296 | $479.0K | 0.00% | +269+0.6% | Added |
| Morgan Stanley | 56,138 | $636.0K | 0.00% | −53,920−49.0% | Reduced |
| BlackRock Inc. | 146,812 | $1.66M | 0.00% | −881−0.6% | Reduced |
| Vanguard Group Inc | 242,461 | $2.75M | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 0 | $0 | 0.00% | −62,676−100.0% | Sold out |